首页> 美国卫生研究院文献>PLoS Clinical Trials >Prediction of Chemical-Protein Interactions Network with Weighted Network-Based Inference Method
【2h】

Prediction of Chemical-Protein Interactions Network with Weighted Network-Based Inference Method

机译:基于加权网络的推理方法预测化学-蛋白质相互作用网络

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chemical-protein interaction (CPI) is the central topic of target identification and drug discovery. However, large scale determination of CPI is a big challenge for in vitro or in vivo experiments, while in silico prediction shows great advantages due to low cost and high accuracy. On the basis of our previous drug-target interaction prediction via network-based inference (NBI) method, we further developed node- and edge-weighted NBI methods for CPI prediction here. Two comprehensive CPI bipartite networks extracted from ChEMBL database were used to evaluate the methods, one containing 17,111 CPI pairs between 4,741 compounds and 97 G protein-coupled receptors, the other including 13,648 CPI pairs between 2,827 compounds and 206 kinases. The range of the area under receiver operating characteristic curves was 0.73 to 0.83 for the external validation sets, which confirmed the reliability of the prediction. The weak-interaction hypothesis in CPI network was identified by the edge-weighted NBI method. Moreover, to validate the methods, several candidate targets were predicted for five approved drugs, namely imatinib, dasatinib, sertindole, olanzapine and ziprasidone. The molecular hypotheses and experimental evidence for these predictions were further provided. These results confirmed that our methods have potential values in understanding molecular basis of drug polypharmacology and would be helpful for drug repositioning.
机译:化学-蛋白质相互作用(CPI)是目标识别和药物发现的中心主题。但是,大规模测定CPI对于体外或体内实验是一个巨大的挑战,而计算机预测由于其低成本和高精度而显示出巨大的优势。在我们之前通过基于网络的推断(NBI)方法进行药物-靶标相互作用预测的基础上,我们在此进一步开发了节点和边缘加权NBI方法来预测CPI。使用从ChEMBL数据库中提取的两个全面的CPI二分网络对方法进行评估,一个网络包含4,741个化合物与97 G蛋白偶联受体之间的17,111个CPI对,另一个包含2,827个化合物与206个激酶之间的13,648个CPI对。对于外部验证集,接收器工作特性曲线下的面积范围为0.73至0.83,这证实了预测的可靠性。通过边缘加权NBI方法确定了CPI网络中的弱相互作用假设。此外,为验证该方法,预测了五种批准的药物的几种候选靶点,即伊马替尼,达沙替尼,塞地多尔,奥氮平和齐拉西酮。进一步提供了这些预测的分子假设和实验证据。这些结果证实了我们的方法在理解药物多药理学的分子基础上具有潜在价值,将有助于药物的重新定位。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号